A world leader in patient-centered care
Training the next generation of cancer researchers
The most advanced treatment options available
View all adult cancer types
View all pediatric cancer types
Susan F. Smith Center for Women's Cancers
Gynecologic CancerBlood CancersCancer Genetics and PreventionCutaneous (Skin) CancerGastrointestinal CancerGenitourinary CancerHead and Neck CancerHematologyMelanomaNeuro-OncologySarcomaStem Cell TransplantThoracic (Lung) Cancer
Blood DisordersBrain TumorsHematologic MalignanciesSolid TumorsStem Cell Transplant
Myles Brown, MD, Brown, director of the Center for Functional Cancer Epigenetics at Dana-Farber Cancer Institute, has been elected to The National Academy of Sciences.
Dana-Farber Cancer Institute has launched DiscoverCareBelieve.org, a new platform to illustrate what sets Dana-Farber apart — in research discovery... in expert, compassionate care... and in our strong belief in progress for people with cancer everywhere.WebsiteVideoWhat do you #DiscoverCareBelieve?
Clinicians at Dana-Farber/Brigham and Women's Cancer Center are now armed with specialized tests to create a precise "tumor profile" for each patient's cancer. Learn about the latest thinking in precision cancer medicine from our researchers and clinicians, and explore a searchable database of clinical trials that focus on targeted therapies by disease, gene, and mutation.
Dana-Farber is teaming up with Fitbit to test if weight loss can help prevent breast cancer recurrence among overweight women with early stage disease. This first of its kind study has potential to create a new standard of treatment for millions of breast cancer patients around the world.
William G. Kaelin, Jr., MD, of Dana-Farber has received the 10th annual Princess Takamatsu Award for "novel and significant work" in cancer from the American Association for Cancer Research (AACR).
One-third of patients with metastatic melanoma in a phase 1 clinical trial have survived five years after treatment with the immunotherapy drug nivolumab, which blocks the PD-1 immune checkpoint, reports a Dana-Farber Cancer Institute scientist.
Colorectal cancers heavily bedecked with tumor-related proteins called neoantigens are likely to be permeated with disease-fighting white blood cells, researchers at Dana-Farber report in a new study.
Dr. Jennifer Ligibel is leading research to see if weight loss can prevent breast cancer recurrence.
Researchers at Dana Farber helped develop a new test called a Rapid Heme Panel to diagnose patients faster.
A study led by Dr. Lisa Diller shows surviving a childhood cancer can take a toll on health, and that young adults who've been through the ordeal often feel aged before their time.
Dr. William Kaelin Jr., said to accelerate President Obama's "moonshot" initiative, collaboration among researchers is critical.
Dr. F. Stephen Hodi led a study showing more than one-third of advanced melanoma patients treated with the immunotherapy drug Opdivo have survived at least five years.
Dr. Rachel Freedman comments on a study showing older black women with human epidermal growth factor receptor 2 (HER2)–positive breast cancer are less likely than their white peers to receive targeted therapy.
Dr. David A. Williams, president of Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, comments on why pediatric cancers should be a priority for research funds.
Drs. Kornelia Polyak, Tari King and Jennifer Ligibel are new leaders in breast cancer research and advocacy for the Komen Scholars international advisory group.
10:00 AM - 11:30 AM
Smith Building, Room 330
In this class you will learn exercises of the mind/body through mindfulness awareness and fluid movement. These techniques will help you to relax, increase concentration, while utilizing the mind, body and spirit to help improve quality of life. This class is open to patients who have been newly diagnosed with cancer, are receiving treatment, or in remission. Family, friends and staff are welcome. Please call the Zakim Center to register at 617-632-3322 or email Zakim_Center@dfci.harvard.edu.
11:30 AM - 1:00 PM
This class will focus on gentle movements and exercises. Learn and practice sitting or standing techniques, as well as slow moving meditation focusing on deep breathing and posture to help relax the mind and strengthen the body. This class is open to patients who have been newly diagnosed with cancer, are receiving treatment, or in remission. Family, friends and staff are welcome. Please call the Zakim Center to register at 617-632-3322 or email Zakim_Center@dfci.harvard.edu.
Mobile Music Open Studio
1:30 PM - 2:30 PM
Experience the new Mobile Music Studio, and explore how creativity through music is a therapeutic and enriching tool for stress and pain management. Using the technology of a fully functioning recording studio, patients can learn studio basics during our drop-in hours or schedule studio time to write and record your own music. No experience is necessary. This program is led by the Zakim Center's Expressive Therapies manager, Heather Woods, MT-BC. Contact the Leonard P. Zakim Center for Integrative Therapies for any questions: 617-632-3322 or email Zakim_Center@dfci.harvard.edu.
Patient referral information, clinical resources and more.
For adults:877-442-3324Quick access: Appointments as soon as the next day for new adult patientsFor children:888-733-4662
Search current cancer clinical trials at Dana-Farber.
There are many ways to support Dana-Farber and the Jimmy Fund.
Top-ranked cancer center in New England for adults (with Brigham and Women's Hospital) — #1 in the nation for children (with Boston Children's Hospital)
Insight features the latest in cancer care and research news from Dana-Farber.Read the blog
Stay current on the latest news by signing up for Spotlight, our email newsletter.View current issueSubscribe now
Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215 | Call us toll-free: